Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Patenting natural products just got harder

Nature Biotechnology volume 32, pages 403–404 (2014)Cite this article

Subjects

The new guidelines draw on two high-profile Supreme Court decisions: The Association for Molecular Pathology versus Myriad, which determined that isolated and purified DNA could not be patented (Nat. Biotechnol. 31, 663–665, 2013) and Mayo versus Prometheus, which ruled that methods of determining optimal drug doses, based on levels of a naturally occurring metabolite were not patent eligible (Nat. Biotechnol. 30, 373–374, 2012).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Canterbury, UK

    Charlotte Harrison

Authors
  1. Charlotte Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harrison, C. Patenting natural products just got harder. Nat Biotechnol 32, 403–404 (2014). https://doi.org/10.1038/nbt0514-403a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0514-403a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing